Abstract:Background: Copper (Cu) is a transition metal active in Fenton redox cycling from reduced Cu+ and H2O2, to oxidized Cu2+ and the hydroxyl radical (·OH) highly reactive oxygen species (ROS). At homeostatic Cu levels, ROS promote cell proliferation, migration, angiogenesis, and wound repair. To limit ROS toxicity, cells use Cu-dependent chaperone proteins, Cu-binding ceruloplasmin, and Cu-modulated enzymes like superoxide dismutases (SOD) like SOD1 and SOD3 to scavenge excess superoxide anions which favour Cu+ reduction, and mitochondrial cytochrome c oxidase, important in aerobic energy production. Because Cu helps drive tumor cell proliferation by promoting growth factor-independent receptor tyrosine kinase signaling, and Cu-dependent MEK1 involved in oncogenic BRAF-V600E signaling, further augmenting bioavailable Cu may promote ROS overproduction, cancer progression and eventually tumor cell death. For these reasons, the following clinically approved copper chelators are being repurposed as anti-cancer agents: a) ammonium tetrathiomolybdate (TTM) used to treat Wilson's disease (copper overload) and Menkes disease (copper deficiency); b) Disulfiram (DSF), used against alcoholism, since it inhibits Aldehyde Dehydrogenase (ALDH1) enzyme, important in ethanol detoxification, and a key target against cancer stem cells. Moreover, TTM and DSF are also relevant in cancer clinical trials, because they increase the uptake of both Cu and Platinum (Pt)-containing anti-cancer drugs, since Pt and Cu share the same CTR1 copper transporter. Purpose: The majority of reports on Cu chelators dealt separately with either TTM, DSF or others. Here, we compare in parallel, the anti-cancer efficacy of low doses of TTM and DSF, asking whether they can be synergistic or antagonistic. The relevance of their unequal ROS inducing abilities and their different behavior as ionophores is also addressed. Significance: The potential of Cu chelators as repurposed anti-cancer drugs, should be greater in patients with higher endogenous Cu levels. Since platinum and Cu share uptake receptors, the synergism by drugs containing these metals should not be under-estimated. The potential of disulfiram or its metabolically active Cu-containing form, to inhibit ALDH1-positive tumor cells is therapeutically very important.

New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer

Copper (II) Synergistic AS1411 Conjunction with Chemical Decaging Reactions for Selective Fluorescence Imaging and Prodrug Activation in Living Systems

Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents

Regenerating Chemotherapeutics through Copper-Based Nanomedicine: Disrupting Protein Homeostasis for Enhanced Tumor Therapy

Synthesis, Characterization, DNA/HSA Interactions, and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand

Potential of Copper and Copper Compounds for Anticancer Applications

Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents

Cancer Pro-oxidant Therapy Through Copper Redox Cycling: Repurposing Disulfiram and Tetrathiomolybdate

Copper Binding Agents Acting as Copper Ionophores Lead to Caspase Inhibition and Paraptotic Cell Death in Human Cancer Cells

Localized Sustained Release of Copper Enhances Antitumor Effects of Disulfiram in Head and Neck Cancer

A novel water-soluble Cu(II) gluconate complex inhibits cancer cell growth by triggering apoptosis and ferroptosis related mechanisms

Synthesis, characterization and biological activity of novel copper complexes containing a β-carboline derivative and amino acids

New copper complexes inducing bimodal death through apoptosis and autophagy in A549 cancer cells

Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes

Dendritic Pyridine–Imine Copper Complexes as Metallo-Drugs

Disulfiram: A novel repurposed drug for cancer therapy

Mixed‐Ligand Mononuclear Copper(II) Complex: Crystal Structure and Anticancer Activity

Copper-mediated Chemodynamic Therapy with Ultra-Low Copper Consumption by Doping Cupric Ion on Cross-Linked (R)-(+)-lipoic Acid Nanoparticles

Cell-penetrating peptide-conjugated copper complexes for redox-mediated anticancer therapy

A nanomedicine approach to targeting cuproplasia in cancer: Labile copper sequestration using polydopamine nanoparticles blocks tumor growth in vivo through altering metabolism and redox homeostasis.

Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review